v3.26.1
Revenue (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Net product revenue$21,403 $14,726 $39,856 $26,327 
Collaboration and other revenue
1,571 832 2,917 1,959 
Revenue$22,974 $15,558 $42,773 $28,286 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended June 30, 2026 and 2025:
Three Months Ended June 30,
20262025
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Cardiometabolic Health:
Mounjaro$4,791 $5,152 $9,943 $3,302 $1,897 $5,199 
Zepbound(1)
4,873 55 4,928 3,380 2 3,381 
Jardiance(2)
616 615 1,232 382 308 690 
Trulicity908 312 1,219 744 348 1,092 
Other cardiometabolic health554 477 1,031 556 425 980 
Total cardiometabolic health11,742 6,611 18,353 8,363 2,980 11,343 
Oncology:
Verzenio845 629 1,474 929 560 1,489 
Other oncology628 468 1,096 490 434 924 
Total oncology1,473 1,097 2,570 1,419 994 2,414 
Immunology:
Taltz539 317 856 549 299 848 
Other immunology251 310 561 152 256 408 
Total immunology790 627 1,417 701 555 1,256 
Neuroscience325 104 429 248 96 344 
Other
84 122 205 83 119 202 
Revenue$14,413 $8,561 $22,974 $10,814 $4,743 $15,558 
(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the U.S.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the six months ended June 30, 2026 and 2025:
Six Months Ended June 30,
20262025
U.S.Outside U.S.TotalU.S.Outside U.S.Total
Cardiometabolic Health:
Mounjaro$9,024 $9,582 $18,605 $5,958 $3,083 $9,041 
Zepbound(1)
9,006 81 9,088 5,685 8 5,693 
Jardiance(2)
1,128 1,218 2,346 692 1,012 1,704 
Trulicity1,508 630 2,138 1,514 673 2,187 
Other cardiometabolic health1,000 936 1,936 1,091 835 1,925 
Total cardiometabolic health21,666 12,447 34,113 14,940 5,611 20,551 
Oncology:
Verzenio1,551 1,224 2,776 1,587 1,062 2,648 
Other oncology1,149 914 2,062 879 835 1,713 
Total oncology2,700 2,138 4,838 2,465 1,896 4,361 
Immunology:
Taltz956 632 1,588 1,025 584 1,610 
Other immunology453 579 1,032 254 480 734 
Total immunology1,409 1,211 2,620 1,279 1,065 2,344 
Neuroscience617 194 811 437 179 616 
Other140 252 392 182 232 414 
Revenue$26,532 $16,241 $42,773 $19,304 $8,983 $28,286 
(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the U.S.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue by geographical area:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue(1):
U.S.$14,413 $10,814 $26,532 $19,304 
Europe4,115 2,574 7,760 4,963 
China941 466 1,635 917 
Japan628 521 1,199 923 
Rest of world2,877 1,182 5,648 2,180 
Revenue$22,974 $15,558 $42,773 $28,286 
(1) Revenue is attributed to the countries based on the location of the customer or other party.